Which has stronger earnings & valuation, MANE or EVO?

Veradermics has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A N/A N/A N/A Evotec $891.97M 1.18 -$117.12M N/A N/A

Is MANE or EVO more profitable?

Veradermics has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Veradermics' return on equity of 0.00% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Evotec -26.20% -24.93% -11.35%

Which has stronger valuation and earnings, NAMS or EVO?

Evotec has higher revenue and earnings than NewAmsterdam Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewAmsterdam Pharma $22.50M 171.77 -$203.82M -$1.79 N/A Evotec $891.97M 1.18 -$117.12M N/A N/A

Which has higher valuation and earnings, TVTX or EVO?

Travere Therapeutics has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Travere Therapeutics $490.73M 8.92 -$25.55M -$0.23 N/A Evotec $891.97M 1.18 -$117.12M N/A N/A

Which has preferable earnings & valuation, KNSA or EVO?

Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kiniksa Pharmaceuticals International $677.56M 5.69 $59.01M $0.90 55.69 Evotec $891.97M 1.18 -$117.12M N/A N/A

Which has stronger valuation & earnings, AMRX or EVO?

Amneal Pharmaceuticals has higher revenue and earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amneal Pharmaceuticals $3.02B 1.44 $72.06M $0.38 35.78 Evotec $891.97M 1.18 -$117.12M N/A N/A

Evotec (EVO) Competitors

$2.96 +0.07 (+2.25%)

As of 12:56 PM Eastern

Compare

EVO vs. MANE, NAMS, TVTX, KNSA, and AMRX

Should you buy Evotec stock or one of its competitors? MarketBeat compares Evotec with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evotec include MANE (MANE), NewAmsterdam Pharma (NAMS), Travere Therapeutics (TVTX), Kiniksa Pharmaceuticals International (KNSA), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry.

How does Evotec compare to Veradermics?

Veradermics (NYSE:MANE) and Evotec (NASDAQ:EVO) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

In the previous week, Veradermics had 8 more articles in the media than Evotec. MarketBeat recorded 8 mentions for Veradermics and 0 mentions for Evotec. Evotec's average media sentiment score of 0.94 beat Veradermics' score of 0.34 indicating that Evotec is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradermics	Neutral
Evotec	Positive

Veradermics has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Veradermics' return on equity of 0.00% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Evotec	-26.20%	-24.93%	-11.35%

5.8% of Evotec shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Veradermics has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	N/A	N/A
Evotec	$891.97M	1.18	-$117.12M	N/A	N/A

Veradermics presently has a consensus target price of $109.00, suggesting a potential upside of 6.98%. Evotec has a consensus target price of $7.00, suggesting a potential upside of 136.89%. Given Evotec's higher probable upside, analysts plainly believe Evotec is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Veradermics beats Evotec on 6 of the 11 factors compared between the two stocks.

How does Evotec compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Evotec (NASDAQ:EVO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, NewAmsterdam Pharma had 4 more articles in the media than Evotec. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 0 mentions for Evotec. Evotec's average media sentiment score of 0.94 beat NewAmsterdam Pharma's score of 0.76 indicating that Evotec is being referred to more favorably in the news media.

Company	Overall Sentiment
NewAmsterdam Pharma	Positive
Evotec	Positive

Evotec has a net margin of -26.20% compared to NewAmsterdam Pharma's net margin of -943.23%. Evotec's return on equity of -24.93% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Evotec	-26.20%	-24.93%	-11.35%

Evotec has higher revenue and earnings than NewAmsterdam Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	171.77	-$203.82M	-$1.79	N/A
Evotec	$891.97M	1.18	-$117.12M	N/A	N/A

NewAmsterdam Pharma presently has a consensus target price of $48.60, suggesting a potential upside of 47.01%. Evotec has a consensus target price of $7.00, suggesting a potential upside of 136.89%. Given Evotec's higher possible upside, analysts clearly believe Evotec is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 1.0% of Evotec shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NewAmsterdam Pharma has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market. Comparatively, Evotec has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market.

Summary

Evotec beats NewAmsterdam Pharma on 8 of the 15 factors compared between the two stocks.

How does Evotec compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Travere Therapeutics has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	8.92	-$25.55M	-$0.23	N/A
Evotec	$891.97M	1.18	-$117.12M	N/A	N/A

Travere Therapeutics presently has a consensus price target of $48.92, suggesting a potential upside of 3.94%. Evotec has a consensus price target of $7.00, suggesting a potential upside of 136.89%. Given Evotec's higher probable upside, analysts plainly believe Evotec is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Travere Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Evotec has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market.

In the previous week, Travere Therapeutics had 12 more articles in the media than Evotec. MarketBeat recorded 12 mentions for Travere Therapeutics and 0 mentions for Evotec. Evotec's average media sentiment score of 0.94 beat Travere Therapeutics' score of 0.59 indicating that Evotec is being referred to more favorably in the news media.

Company	Overall Sentiment
Travere Therapeutics	Positive
Evotec	Positive

Travere Therapeutics has a net margin of -4.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Evotec	-26.20%	-24.93%	-11.35%

5.8% of Evotec shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Travere Therapeutics beats Evotec on 8 of the 14 factors compared between the two stocks.

How does Evotec compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Evotec's net margin of -26.20%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Evotec	-26.20%	-24.93%	-11.35%

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 1.0% of Evotec shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	5.69	$59.01M	$0.90	55.69
Evotec	$891.97M	1.18	-$117.12M	N/A	N/A

Kiniksa Pharmaceuticals International has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market. Comparatively, Evotec has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market.

Kiniksa Pharmaceuticals International currently has a consensus target price of $60.86, suggesting a potential upside of 21.42%. Evotec has a consensus target price of $7.00, suggesting a potential upside of 136.89%. Given Evotec's higher possible upside, analysts clearly believe Evotec is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Kiniksa Pharmaceuticals International had 3 more articles in the media than Evotec. MarketBeat recorded 3 mentions for Kiniksa Pharmaceuticals International and 0 mentions for Evotec. Kiniksa Pharmaceuticals International's average media sentiment score of 0.99 beat Evotec's score of 0.94 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Overall Sentiment
Kiniksa Pharmaceuticals International	Positive
Evotec	Positive

Summary

Kiniksa Pharmaceuticals International beats Evotec on 11 of the 14 factors compared between the two stocks.

How does Evotec compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Amneal Pharmaceuticals has higher revenue and earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.44	$72.06M	$0.38	35.78
Evotec	$891.97M	1.18	-$117.12M	N/A	N/A

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Amneal Pharmaceuticals had 3 more articles in the media than Evotec. MarketBeat recorded 3 mentions for Amneal Pharmaceuticals and 0 mentions for Evotec. Evotec's average media sentiment score of 0.94 beat Amneal Pharmaceuticals' score of 0.72 indicating that Evotec is being referred to more favorably in the news media.

Company	Overall Sentiment
Amneal Pharmaceuticals	Positive
Evotec	Positive

Amneal Pharmaceuticals currently has a consensus price target of $15.17, indicating a potential upside of 11.56%. Evotec has a consensus price target of $7.00, indicating a potential upside of 136.89%. Given Evotec's higher possible upside, analysts plainly believe Evotec is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Amneal Pharmaceuticals has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Evotec has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Evotec	-26.20%	-24.93%	-11.35%

Summary

Amneal Pharmaceuticals beats Evotec on 10 of the 14 factors compared between the two stocks.

Get Evotec News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVO vs. The Competition

Export

Metric	Evotec	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.05B	$2.97B	$6.45B	$12.42B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	N/A	18.16	23.89	24.35
Price / Sales	1.18	310.02	524.38	119.30
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	1.14	3.96	10.06	6.74
Net Income	-$117.12M	$75.85M	$3.56B	$337.03M
7 Day Performance	-0.17%	-1.32%	-0.60%	0.24%
1 Month Performance	N/A	N/A	N/A	-1.60%
1 Year Performance	-27.93%	23.82%	29.29%	34.04%

Evotec Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVO Evotec	3.1277 of 5 stars	$2.96 +2.2%	$7.00 +136.9%	-28.3%	$1.05B	$891.97M	N/A	4,553	Gap Up
MANE MANE	N/A	$101.42 -0.2%	$100.00 -1.4%	N/A	$4.24B	N/A	N/A	19	Analyst Forecast Gap Down
NAMS NewAmsterdam Pharma	3.2956 of 5 stars	$35.44 flat	$48.00 +35.4%	+71.8%	$4.14B	$22.50M	N/A	4	Gap Up
TVTX Travere Therapeutics	1.8887 of 5 stars	$44.43 flat	$47.83 +7.7%	+193.5%	$4.13B	$490.73M	N/A	460	Analyst Forecast
KNSA Kiniksa Pharmaceuticals International	4.4029 of 5 stars	$53.24 flat	$60.86 +14.3%	+64.4%	$4.10B	$677.56M	59.16	220

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVO) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evotec (EVO) Competitors

EVO vs. MANE, NAMS, TVTX, KNSA, and AMRX

How does Evotec compare to Veradermics?

Summary

How does Evotec compare to NewAmsterdam Pharma?

Summary

How does Evotec compare to Travere Therapeutics?

Summary

How does Evotec compare to Kiniksa Pharmaceuticals International?

Summary

How does Evotec compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evotec (EVO) Competitors

EVO vs. MANE, NAMS, TVTX, KNSA, and AMRX

How does Evotec compare to Veradermics?

Does the media favor MANE or EVO?

Is MANE or EVO more profitable?

Do institutionals & insiders have more ownership in MANE or EVO?

Which has stronger earnings & valuation, MANE or EVO?

Do analysts prefer MANE or EVO?

Summary

How does Evotec compare to NewAmsterdam Pharma?

Does the media prefer NAMS or EVO?

Is NAMS or EVO more profitable?

Which has stronger valuation and earnings, NAMS or EVO?

Do analysts rate NAMS or EVO?

Do insiders and institutionals hold more shares of NAMS or EVO?

Which has more risk & volatility, NAMS or EVO?

Summary

How does Evotec compare to Travere Therapeutics?

Which has higher valuation and earnings, TVTX or EVO?

Do analysts recommend TVTX or EVO?

Which has more volatility and risk, TVTX or EVO?

Does the media prefer TVTX or EVO?

Is TVTX or EVO more profitable?

Do institutionals & insiders hold more shares of TVTX or EVO?

Summary

How does Evotec compare to Kiniksa Pharmaceuticals International?

Is KNSA or EVO more profitable?

Do institutionals and insiders hold more shares of KNSA or EVO?

Which has preferable earnings & valuation, KNSA or EVO?

Which has more risk & volatility, KNSA or EVO?

Do analysts recommend KNSA or EVO?

Does the media favor KNSA or EVO?

Summary

How does Evotec compare to Amneal Pharmaceuticals?

Which has stronger valuation & earnings, AMRX or EVO?

Do institutionals & insiders believe in AMRX or EVO?

Does the media prefer AMRX or EVO?

Do analysts rate AMRX or EVO?

Which has more risk & volatility, AMRX or EVO?

Is AMRX or EVO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools